TCT 2022

TCT 2022 | PCSK9 Inhibitor in Patients with STEMI to Lower LDL Cholesterol

In patients with ST-elevation myocardial infarction (STEMI), early treatment with statins —regardless of low-density lipoprotein (LDL) cholesterol...

TCT 2022 | Angioplasty vs. Surgery: The BEST Study Long-Term Results

The BEST study was a prospective, randomized study to compare percutaneous coronary intervention (PCI) with everolimus-eluting stents...

TCT 2022 | BYPASS CTCA

Studies have shown that the use of computed tomography cardiac angiography (CTCA) prior invasive coronary angiography (ICA)...

TCT 2022 | PROTECTED TAVR

Stroke is still a major complication of transcatheter aortic valve replacement (TAVR), with a 30-day mortality of...

TCT 2022 | Edge-to-Edge Repair in Patients with Severe Mitral Insufficiency and Cardiogenic Shock: Analysis of the TVT Registry

Approximately 1 in 5 patients admitted for cardiogenic shock (CS) were observed to have moderate to severe...

TCT 2022 | CLASP II D TRIAL: Transcatheter Edge-to-Edge Repair for Mitral Regurgitation in Patients at Prohibitive Risk

The CLASP IID study was a prospective randomized study to assess the efficacy and effectiveness of the...

TCT 2022 | AMULET IDE: Events at 3 Years Using the AMULET Appendage Closure Device

The aim of this study was to assess the 3-year efficacy for the endpoints of the AMULET...

SYMPLICITY HTN-3 Trial. Evolution at 3 Years

The SYMPLICITY 3-year outcomes are out. Bear in mind this is the largest study we have had...